Preview

Современная ревматология

Расширенный поиск

Рекомендации по ведению больныхсистемной красной волчанко й в клинической практике(по материалам рекомендаций Европейскойантиревматической лиги - EULAR)

https://doi.org/10.14412/1996-7012-2011-645

Полный текст:

Литература

1. <div><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010;429-81.</p><p>Abu-Shakra M., Urowitz M.B., Gladman D.D. et al. Mortality studies in systemic lupus erythematosus. Results from a single center. J Rheumatol 1995;22:1265-70.</p><p>Yazdany J., Panopalis P., Gillis J.Z. et al. A quality indicator set for systemic lupus erythematosus. Arthr Rheum 2009;61(3):370-7.</p><p>Demas K.L., Costenbader K.H. Disparities in lupus care and outcomes. Curr Opin Rheumatol 2009;21(2):102-9.</p><p>Centre for Evidence-Based Medicine. EBM Tools. Finding the Evidence. Levels of Evidence. University of Oxford, 2001. http:/www.cebm.net/index.aspx?o=1025 (accessed 15 February 2009).</p><p>Dougados M., Betteridge N., Burmester G.R. et al. EULAR standardied operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63(9):1172-6.</p><p>Strand V., Gladman D., Isenberg D. et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26(2):490-7.</p><p>Ramsey-Goldman R., Isenberg D.A. Systemic lupus erythematosus measures. Arthr Care Res 2003;49(5 Suppl.):225-33.</p><p>Bombardier C., Gladman D.D., Urowitz M.B. et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthr Rheum 1992;35:630-40.</p><p>Petri M., Kim M.Y., Kalunian K.C. et al. For the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.</p><p>Hay E.M., Bacon P.A., Gordon C. et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.</p><p>Vitali C., Bencivelli W., Isenberg D.A. et al. The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.</p><p>Насонова В.А., Астапенко М.Г. Клиническая ревматология. Руководство для врачей. М.: Медицина, 1989;156.</p><p>Ruperto N., Hanrahan L.M., Alarcon G.S. et al. International consensus for a definition of disease flare in lupus. Lupus 2010;0:1-10.</p><p>Gladman D.D., Urowitz M.B., Goldsmith C. et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthr Rheum 1997;40:809-13.</p><p>Calvo-Alеn J., Toloza S.M., Fernаndez M. et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthr Rheum 2005;52(7):2060-8.</p><p>Asanuma Y., Oeser A., Shintani A.K. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2407-15.</p><p>Bruce I.N., Urowitz M.B., Gladman D.D. et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthr Rheum 2003;48(11):3159-67.</p><p>Esdaile., J.M., Abrahamowicz M., Grodzicky T. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr Rheum 2001;44(10):2331-7.</p><p>Manzi S., Selzer F., Sutton-Tyrrell K. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthr Rheum 1999;42(1):51-60.</p><p>Wajed J., Ahmad Y., Durrington P.N. et al. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatol (Oxford) 2004;43:7-12.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium medicum 2010;2(12):112-7.</p><p>Almehed K., Forsblad d'Elia H., Kvist G. et al. Prevalence and risk factors of osteoporosis in female SLE patients - extended report. Rheumatol (Oxford) 2007;46(7):1185-90.</p><p>Bultink I.E., Lems W.F., Kostense P.J. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthr Rheum 2005;52(7):2044-50.</p><p>Bernatsky S., Boivin J.F., Joseph L. et al. An international cohort study of cancer in systemic lupus erythematosus. Arthr Rheum 2005;52(5):1481-90.</p><p>Ognenovski V.M., Marder W., Somers E.C. et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31(9):1763-7.</p><p>Bernatsky S.R., Cooper G.S., Mill C. et al. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 2006;33(1):45-9.</p><p>Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V. et al. High risk of tuberculosis in systemic lupus erythematosusLupus 2006;15(4):232-5.</p><p>Abu-Shakra M., El-Sana S., Margalith M. et al. Hepatitis B and C viruses serology in patients with SLE. Lupus 1997;6(6):543-4.</p><p>http:/www.cdc.gov/mmwr/previewmmwrhtml/00001642.htm</p><p>Yoda Y., Hanaoka R., Ide H. et al. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia. Mod Rheumatol 2006;16(3):137-42.</p><p>Ramos-Casals M., Cuadrado M.J., Alba P. et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 2008;87(6):311-8.</p><p>Белов Б.С., Балабанова Р.М. Вакцинации при ревматических заболеваниях. Науч-практич ревматол 2010;4:12-3.</p><p>Conti F., Rezai S., Valesini G. Vaccination and rheumatic disease: is there still a dillemma- Curr Rheumatol Rev 2007;3:79-91.</p><p>Battafarano D.F., Battafarano N.J., Larsen L. et al. Antigen-specific antibody responses in lupus patients following immunization. Arthr Rheum 1998;41(10):1828-34.</p><p>Klippel J.H., Karsh J., Stahl N.I. et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthr Rheum 1979;22(12):1321-5.</p><p>Ng W.L., Chu C.M., Wu A.K. et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 2006;99(1):37-47.</p><p>Tokano Y., Yagita H., Iida N. et al. Relation between the level of IgG subclasses and infections in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1988;87(1):55-8.</p><p>Hoffman I.E., Peene I., Meheus L. et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63(9):1155-8.</p><p>Kavanaugh A.F., Solomon D.H. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthr Rheum 2002;47:546-55.</p><p>Bertsias G., Ioannidis J.P., Boletis J. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.</p><p>Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.</p><p>Ruiz-Irastorza G., Egurbide M.V., Martinez-Berriotxoa A. et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004;13:900-5.</p><p>Moroni G., Ventura D., Riva P. et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36.</p><p>Stone J.H., Amend W.J., Criswell L.A. Outcome of renal transplantation in systemic lupus erythematosus. Semin Arthr Rheum 1997;27:17-26.</p><p>Ho A., Barr S.G., Magder L.S. et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthr Rheum 2001;44:2350-7.</p><p>Gordon C., Jayne D., Pusey C. et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009;18:257-63.</p><p>Mok C.C., Ho C.T., Chan K.W. et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthr Rheum 2002;46:1003-13.</p><p>Mok C.C., Ying K.Y., Tang S. et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthr Rheum 2004;50:2559-68.</p><p>Williams R.C. Jr., Harmon M.E., Burlingame R. et al. Studies of serum Creactive protein in systemic lupus erythematosus. J Rheumatol 2005;32:454-61.</p><p>Rothfield N., Sontheimer R.D., Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348-62.</p><p>Krathen M.S., Dunham J., Gaines E. et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthr Rheum 2008;59:338-44.</p><p>Ciruelo E., de la Cruz J., Lоpez I. et al. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthr Rheum 1996;39:2028-34.</p><p>Illei G.G., Takada K., Parkin D. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthr Rheum 2002;46:995-1002.</p><p>Moroni G., Quaglini S., Maccario M. et al. «Nephritic flares» are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53.</p><p>Hanly J.G. The neuropsychiatric SLE SLICC inception cohort study. Lupus 2008;17:1059-63.</p><p>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthr Rheum 1999;42(4):599-608.</p><p>Denburg S.D., Stewart K.E., Hart L.E. et al. How soft are soft neurological signs- The relationship of subjective neuropsychi atric complaints to cognitive function in systemic lupus erythematosus. J Rheumatol 2003;30:1006-10.</p><p>Hanly J.G., Urowitz M.B., Sanchez-Guerrero J. et al. Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthr Rheum 2007;56(1):265-73.</p><p>Bertsias G.K., Ioannidis J.P.A., Aringer M. et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.</p><p>Лисицына Т.А., Кошелева Н.М. Антималярийные препараты в терапии системной красной волчанки: прошлое, настоящее, будущее. Совр ревматол 2010;2:80-7.</p><p>Da Silva J.A., Jacobs J.W., Kirwan J.R. et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.</p></div><br />


Для цитирования:


Попкова Т.В., Лисицына Т.А. Рекомендации по ведению больныхсистемной красной волчанко й в клинической практике(по материалам рекомендаций Европейскойантиревматической лиги - EULAR). Современная ревматология. 2011;5(1):4-12. https://doi.org/10.14412/1996-7012-2011-645

For citation:


Popkova T.V., Lisitsyna T.A. Rekomendatsii po vedeniyu bol'nykhsistemnoy krasnoy volchanko y v klinicheskoy praktike(po materialam rekomendatsiy Evropeyskoyantirevmaticheskoy ligi - EULAR). Modern Rheumatology Journal. 2011;5(1):4-12. (In Russ.) https://doi.org/10.14412/1996-7012-2011-645

Просмотров: 626


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)